Elizabeth Poplin is an Oncology physician affiliated with Rutgers. OpenAlex indexes 120 publications with 4,459 citations (h-index 28); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Robert Wood Johnson Place
New Brunswick, NJ 089031928
Telephone
732-235-7840Registry record last updated 10 Jan 2011.
Clinical trials
- Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
Sponsor: National Cancer Institute (NCI)
- First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients
Sponsor: University of Medicine and Dentistry of New Jersey
- Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer
Sponsor: University of Medicine and Dentistry of New Jersey
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Opioid Agonist100%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1998–1999 per NIH RePORTER. The latest:
- INTRAPERITONEAL GEMCITABINE--PHASE I &PARMACOKINETICS
Univ of Med/dent Nj-R W Johnson Med Sch
FY1999R03CA079510 - INTRAPERITONEAL GEMCITABINE--PHASE I &PARMACOKINETICS
Univ of Med/dent Nj-R W Johnson Med Sch
FY1998R03CA079510
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Management of locally advanced rectal cancer in the elderly: a critical review and algorithm
Journal of Gastrointestinal Oncology
2018 - Decision-Making Strategy for Rectal Cancer Management Using Radiation Therapy for Elderly or Comorbid Patients
International Journal of Radiation Oncology*Biology*Physics
2018 - Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis
Digestive Diseases and Sciences
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Sherine Gabriel, MD
Rutgers
Julius Gardin, MD
Rutgers
Abraham Aviv, MD
Rutgers
Partho Sengupta, MD, DM
Rutgers
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”